EMA’s panel backs a targeted therapy, which reduces lymphadenopathy and restores B-cell populations in patients with activated phosphoinositide 3-kinase delta syndrome.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/rare-immune-disorder-drug-wins-eu-panel-support-2026a10009n5?src=rss
Author :
Publish date : 2026-03-30 13:24:00
Copyright for syndicated content belongs to the linked Source.
